CTOs on the Move

Valitor

www.valitorbio.com

 
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.valitorbio.com
  • East Bay Innovation Center 820 Heinz Avenue
    Berkeley, CA USA 94710
  • Phone: 510.969.9246

Executives

Name Title Contact Details

Similar Companies

SuperGen

SuperGen Inc. is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eurofins Genomics

Eurofins Genomics is an international provider of DNA sequencing services, oligonucleotide synthesis products and bioinformatic services. The company’s strength is its strong customer orientation, fast service and high quality products including a seri...

California Life Sciences Association

California Life Sciences Association (CLSA) advances Californias world-leading life sciences innovation ecosystem

Coastal Pharma Group

Coastal Pharma Group is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mind Medicine

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.